David Choi, PharmD

Clinical Pharmacy Specialist - Inflammatory Bowel Disease
University of Chicago Medicine

[David Choi, PharmD @IBDPharmD]

The current prior authorization process leads to unnecessary delays that is detrimental to patient care! We need prior authorization reform now! @IBDMD @DocCohenIBD @UChicagoIBD @UChicagoGI @CrohnsColitisFn #IBD https://t.co/OhtQfoDW38

[David Choi, PharmD @IBDPharmD]

@costplusdrugs also has tofacitinib available cash price ranging from $25-29 per month. This could be a game changer getting pediatric patients on tofacitinib when insurance is refusing to cover It! @amelia_kellar @CrohnsColitisFn @DrPasternak_IBD @BradDConstantMD

[David Choi, PharmD @IBDPharmD]

Update: Tofacitinib generics have officially launched and being dispensed. There are true generics and you can confirm with the FDA Orange Book regarding therapeutic equivalence/automatic substitutions. #IBD #GItwitter

https://t.co/8i77iFBjAN

[David Choi, PharmD @IBDPharmD]

@TenzinChodenMD @UChicagoGI @UChicagoIBD

[David Choi, PharmD @IBDPharmD]

New primer in @AJGastro breaks down how Medicare covers advanced therapies for #IBD — must-read for clinicians navigating biologics & the ever-changing reimbursement landscape. 💊
Understanding the system = better access for your patients. #GITwitter #IBD
https://t.co/zdIZKMOFMY

[David Choi, PharmD @IBDPharmD]

Infusion centers are turning away patients on infliximab biosimilars due to negative reimbursement rates and it's impacting pt care. If infusion center cannot provide these infusions, don't forget: Zymfentra (infliximab-dyyb SC) may be an option for patients! #IBD #GITwitter

[David Choi, PharmD @IBDPharmD]

Super excited to share our recent publication evaluating #pharmacist directed treat to target for #IBD patients! IBD pharmacists can play an important role to help optimizing patient outcomes! #GITwitter @IBDMD @UChicagoGI @UChicagoIBD

https://t.co/BvjCU5Cla6

[David Choi, PharmD @IBDPharmD]

@AdamFayeMD @DCharabaty @MondayNightIBD @abbvie @JNJInnovation @TakedaPharma @DrJordanAxelrad @JeanFredericCo1 @IBDimmunology @DrsMeena @clivejmiranda @datadriven_tdoc @IBD_FloMD @JHashashMD @MLongMD @DavidHudesmanMD @shannonchangmd @SimonHongMD @HolmerMd @DrMikeDolinger @ryanungaro @EdwardLoftus2 @EdBarnesMD @BenClickMD @fudmanMD @tommasoparigi @AndresYarur @ownyourcrohns @JustinFieldMD @MeganMurphyGI @AmyStewartNP @LindsayClarkeMD @KDeFelice_IBD @AimenKhanMD @EdithHoMD @IBD_DrEMF @ElisaBodenIBDMD @SalamBachour @RahulSDalalMD @md_ayanna Are we missing out on a strong therapy to help induce remission in very symptomatic patients because of concerns for adverse events due to long term use of JAKi? Sometimes JAKi are completely avoided for older patients due to BBW but still should be utilized for patients.

[David Choi, PharmD @IBDPharmD]

@AdamFayeMD @MondayNightIBD @DCharabaty @abbvie @JNJInnovation @TakedaPharma If we were to add on an additional therapy (TNF-a or JAKi) early to IL23 to help patient get deep remission and eventually stop TNF/JAK, should we be concerned with adverse events with short term use in this patient or are the risks with longer use of therapies?

[David Choi, PharmD @IBDPharmD]

@DCharabaty @AdamFayeMD @MondayNightIBD @abbvie @JNJInnovation @TakedaPharma @DrJordanAxelrad @JeanFredericCo1 @IBDimmunology @DrsMeena @clivejmiranda @datadriven_tdoc @IBD_FloMD @JHashashMD @MLongMD @DavidHudesmanMD @shannonchangmd @SimonHongMD @HolmerMd @DrMikeDolinger @ryanungaro @EdwardLoftus2 @EdBarnesMD @BenClickMD @fudmanMD @tommasoparigi @AndresYarur @ownyourcrohns @JustinFieldMD @MeganMurphyGI @AmyStewartNP @LindsayClarkeMD @KDeFelice_IBD @AimenKhanMD @EdithHoMD @IBD_DrEMF @ElisaBodenIBDMD @SalamBachour @RahulSDalalMD @md_ayanna Considering the duration of therapies and potential adverse events, particularly in light of the ORAL surveillance study with a median follow-up of 4 years, a key question arises: Is JAKi safe for short-term use early on to induce remission without concerns for adverse events?

[David Choi, PharmD @IBDPharmD]

@AdamFayeMD @MondayNightIBD @DCharabaty @abbvie @JNJInnovation @TakedaPharma How long has the patient been treated with IL23 or are we still waiting to see the clinical response to kick in slowly especially if it can take up to 12 weeks to see response. If still early any considerations for bridging patient or combination therapy?

[David Choi, PharmD @IBDPharmD]

@DCharabaty @joshsteinbergMD @MondayNightIBD @SchwartzbergMD @ShaziaMSiddique @IBDPharmacist @JohnRTMonsonMD @john_damianosMD @UnivArizonaIBD @fudmanMD @MariannySulb @ShomronH @ibddoctor @askIBDdoc @ibddocalex @AGA_Gastro Another consideration is thinking about the cost effectiveness of inpatient IFX 10MG/KG vs 2-3 days of Rinvoq 45 mg daily to discharge. With more scrutiny of minimizing inpatient cost, and increased pressure for minimizing LOS, should JAKi be used more often?

[David Choi, PharmD @IBDPharmD]

New dyslipidemia guidelines have brought back LDL goals, does this change your management of JAKi (upadacitinib, tofacitinib) lipid changes??? #IBD #GITwitter #dyslipidemia

[David Choi, PharmD @IBDPharmD]

Pharmacists advancing IBD care! Join the 2026 IBD Pharmacist Virtual Symposium for expert discussions on IBD therapy, patient care, and pharmacy innovation.

Register: https://t.co/8OZ775dpFd
#IBD #GITwitter @IBDProNews

[David Choi, PharmD @IBDPharmD]

@charlie_lees Which IBD phenotypes do you consider to be ideal to check FCP and who would you never recommend checking FCP??

[David Choi, PharmD @IBDPharmD]

Biosimilars significantly contributed to cost savings to US Healthcare but we need transparency for who is actually benefiting from the cost savings! Patients are experiencing higher out of pocket costs with biosimilars, copay should be waived!! 💸🏥 #Biosimilars #IBD #GITwitter

[David Choi, PharmD @IBDPharmD]

Second year of the IBD Pharmacist track at #AIBD2025 with @GI_PharmD! Amazing to see my amazing colleagues and thank you for the support of IBD pharmacists. Thank you to @AIBDNetwork @MLongMD @miguelregueiro @MRegueiroMD @DrCoreySiegel #GI #IBD #GITwitter

[David Choi, PharmD @IBDPharmD]

Had a blast with @PDulaiMD the first preconference track @AIBDNetwork 2025 regarding IBD Treatment 101!! Clinical takeaways to give confidence to caring for IBD pts! #aibd2025 #GITwitter #IBD thank you to @MLongMD @DrCoreySiegel @MRegueiroMD

[David Choi, PharmD @IBDPharmD]

@amelia_kellar @joelle_stpierre @DrMikeDolinger @mattsmyth_gi @KrugCleveland @IBDMD Congratulations!!!

[David Choi, PharmD @IBDPharmD]

We had an amazing 2025 IBD Pharmacist Virtual Symposium to share best practices and tips and tricks!!! You can find the recording of the symposium here!! #IBD #GITwitter #clinicalpharmacy @IBDProNews

[Crohn’s & Colitis Foundation IBD Pro @IBDProNews]

Watch the 2025 IBD Pharmacist Virtual Symposium where experts from across the nation share the latest in IBD treatment strategies, emerging therapies, and real-world patient care challenges. https://t.co/rTHpzKQSlm

[Russell Yanofsky @RussellYanofsky]

Check out our brief report in the @AmJGastro !

We report on 8 patients who developed an eczematous eruption following discontinuation of their JAK inhibitor, with 2 patients having biopsy-proven atopic dermatitis @IBDMD @UChicagoIBD

https://t.co/wqz9hgGutr